as 05-20-2024 9:31am EST
Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products, leveraging its proprietary CodeEvolver directed evolution technology platform. The firm's products and services include Biocatalysts and Enzymes. The company generates majority of its revenue through product sales and also licenses its technology platform CodeEvolver to pharmaceutical companies enabling them to use this technology, in-house, to engineer enzymes for their own businesses. Geographically, it derives revenue from the United States, Ireland, Switzerland, China and other markets.
Founded: | 2002 | Country: | United States |
Employees: | N/A | City: | REDWOOD CITY |
Market Cap: | 261.1M | IPO Year: | 2010 |
Target Price: | $7.50 | AVG Volume (30 days): | 598.6K |
Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.93 | EPS Growth: | N/A |
52 Week Low/High: | $1.45 - $4.91 | Next Earning Date: | 05-02-2024 |
Revenue: | $74,234,000 | Revenue Growth: | -36.13% |
Revenue Growth (this year): | -4.92% | Revenue Growth (next year): | -5.09% |
Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Dorgan Byron L | CDXS | Director | Nov 15 '23 | Sell | $2.11 | 20,000 | $42,168.00 | 193,461 | SEC Form 4 |
CDXS Breaking Stock News: Dive into CDXS Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 days ago
Simply Wall St.
16 days ago
Insider Monkey
17 days ago
Thomson Reuters StreetEvents
17 days ago
GuruFocus.com
17 days ago
GuruFocus.com
18 days ago
Associated Press Finance
18 days ago
GlobeNewswire
18 days ago